A groundbreaking study from Oregon Health & Science University (OHSU) unveils a previously unrecognized role of the notorious cancer-driving protein MYC. Long established as a central player in tumor growth due to its gene-activating properties, MYC now emerges as a direct participant in DNA repair mechanisms that cancer cells exploit to survive genotoxic stress. This discovery illuminates new pathways for enhancing cancer treatment efficacy, particularly in aggressive cancers like pancreatic adenocarcinoma, where treatment resistance is a formidable hurdle.
MYC’s traditional role has been well-characterized: as a transcription factor in the cell nucleus, it orchestrates the expression of genes that govern cellular proliferation and metabolism. This relentless drive for growth, however, is a double-edged sword. Rapid proliferation frequently induces DNA damage and replication stress, threatening genomic integrity. Intriguingly, researchers have discovered that beyond switching genes on and off, a phosphorylated form of MYC specifically targets sites of DNA double-strand breaks, physically recruiting DNA repair proteins to maintain tumor cell survival.
The study highlights serine 62 phosphorylation of MYC as a critical modification that enables its association with damaged DNA. This post-translational modification marks a departure from MYC’s canonical transcriptional activities, positioning it directly at the loci of DNA lesions. By facilitating the assembly of repair complexes, MYC empowers cancer cells to resist the cytotoxic effects of chemotherapy and radiation, both of which traditionally inflict lethal DNA damage.
This newly identified function poses profound implications for oncologic therapies. Since MYC activity assists tumor cells in rapidly repairing DNA, it effectively diminishes the destructive impact of genotoxic treatments. Consequently, tumors with elevated MYC levels often exhibit striking resilience, leading to treatment failure and poor prognoses. Pancreatic cancer, notable for its high MYC expression and dismal survival rates, exemplifies a malignancy where targeting this repair axis could transform clinical outcomes.
The researchers conducted an elaborate series of experiments using patient-derived pancreatic cancer cells and extensive tumor data analysis. They established a strong correlation between heightened MYC activity, increased DNA repair proficiency, and aggressive tumor behavior. Tumors expressing high levels of phosphorylated MYC demonstrated enhanced survival under chemotherapy-induced DNA damage, unveiling a molecular mechanism underlying therapeutic resistance in notoriously intractable cancers.
Perhaps most striking is the paradigm shift this research offers in targeting MYC. Historically branded “undruggable” due to its structural complexity and ubiquity in normal cellular processes, MYC presents formidable challenges for selective inhibition. However, the discrete role of MYC in DNA repair—distinct from its broader transcriptional responsibilities—offers a precision target. By disrupting MYC’s recruitment to DNA breaks without dismantling its normal functions, future therapies could sensitize tumors to DNA-damaging agents while sparing healthy tissue.
OHSU is already pioneering investigation into this therapeutic avenue through clinical trials of a novel MYC inhibitor named OMO-103. Conducted under a “window of opportunity” framework, this trial aims to assess the drug’s impact on MYC activity and DNA repair dynamics in patients with advanced pancreatic cancer. Such studies represent the vanguard of precision oncology, potentially overcoming long-standing barriers that have hindered effective MYC targeting.
This research not only sheds light on MYC’s multifaceted role in cancer biology but also redefines fundamental concepts of tumor adaptability. By co-opting DNA repair mechanisms, MYC enables cancer cells to thrive in the face of profound genotoxic stress—a hallmark of both tumor development and treatment regimens. Understanding these intricate molecular relationships provides a blueprint for novel intervention strategies designed to dismantle tumor defenses.
Given the pressing clinical need, particularly in malignancies refractory to current therapies, this discovery serves as a beacon of hope. It underscores the necessity of integrating molecular insights into therapeutic design, aiming not just to halt tumor growth but to thwart their ability to survive assault. As MYC’s non-canonical function in DNA repair comes into sharper focus, the oncology community moves closer to breakthroughs that could substantially prolong and improve patient lives.
In summary, the elucidation of MYC’s role in facilitating DNA repair under genotoxic stress elucidates a vital mechanism behind chemotherapy and radiation resistance. This insight presents a fertile ground for developing targeted inhibitors that could potentially tip the balance in favor of treatment success, particularly against aggressive tumors like pancreatic cancer. Continued research and clinical validation hold promise for revolutionizing how we combat one of the deadliest forms of cancer.
Subject of Research: Role of MYC in DNA repair and cancer cell survival under genotoxic stress
Article Title: MYC serine 62 phosphorylation promotes its association with DNA double strand breaks to facilitate repair and cell survival under genotoxic stress
News Publication Date: 15-May-2026
Web References: http://dx.doi.org/10.1101/gad.352832.125
Image Credits: OHSU/Christine Torres Hicks
Keywords: Pancreatic cancer, Chemotherapy, DNA damage, MYC protein, DNA repair, Genotoxic stress, Cancer resistance, Molecular oncology, Serine 62 phosphorylation, Tumor survival mechanisms
